Clinical trials: Hepatic Function
Psoriasis Chronic, Liver Fibrosis
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
Main objectives and outcome measures. 1. Establish prevalence of and factors contributing to fatty liver disease and liver fibrosis in patients with psoriasis. Fatty liver disease diagnosed via ultrasound.
- Conditions
- Psoriasis Chronic, Liver Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease
- Trial name
- CORE (NCT02174367)
- Testing
- Transient elastography
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- King's College London
Menopause, Quality of Life
Black Cohosh Extract for Treatment of Moderate to Severe Menopausal Symptoms
Compare the treatment efficacy of black cohosh extract 80 mg daily and placebo for moderate to severe menopausal symptoms
- Trial name
- BCOMS (NCT02093650)
- Testing
- black cohosh extract
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Navamindradhiraj University
Liver Function Tests Abnormalities
Liver Function Test Abnormalities in COVID-19
With the increasing number of COVID-19 infected patients, several studies reported that the liver is the most frequently affected organ after lung damage.
- Trial name
- COVID-19 (NCT04763395)
- Testing
- No intervention
- Where
- Egypt
- Volunteers
- 118 people
- Sponsor
- Sohag University
HIV, Tuberculosis
Preliminary Evaluation of a Point-Of-Care Liver Function Test
The proposed preliminary field evaluation will compare a point-of-care (POC) transaminase test with the standard of care test used in an HIV clinic at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam.
- Conditions
- HIV, Tuberculosis, Drug-Induced Liver Injury
- Trial name
- DFA (NCT01705041)
- Testing
- Diagnostics for All liver function test (LFT)
- Where
- Vietnam
- Volunteers
- 700 people
- Sponsor
- PATH
Hepatic Function Abnormal
A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment
In human, metabolic hepatic clearance represents a significant part of the total clearance of fexinidazole and could be decreased in patients with liver impairment, leading to some overexposure, and conversely, the formation of…
- Trial name
- NCT05607173
- Testing
- Fexinidazole (HOE239)
- Where
- 2 sites in Bulgaria, France
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Sanofi
Liver Transplant; Complications
Effect of N_Acetylcysteine on Liver Functions in Donors in Living Liver Transplantation
our practice for the past 10 years we have noticed a transitional impairment of liver function (elevated liver enzymes, total and direct bilirubin, and elevated serum lactate levels) following donors' liver resection.
- Trial name
- NCT03634566
- Testing
- N-Acetylecysteine
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Cirrhosis, Acute Liver Failure
Evaluation of Cardiac Function in Acutely Decompensated Cirrhosis
This project aims to investigate cardiac function in patients with cirrhosis in the acute setting. Acute decompensation and acute-on-chronic liver failure are major events in the life of a patient as they herald disease…
- Conditions
- Cirrhosis, Acute Liver Failure, Cardiomyopathies
- Trial name
- DYNACORD-AD (NCT05413083)
- Where
- Romania
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Colentina
Liver Metastases
Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases
Background: Anatomical (traditional) stereotactic body radio therapy(SBRT) treatment planning assumes homogenous distribution of function in the normal liver tissue.
- Trial name
- NCT01861873
- Testing
- measuring liver function by 18-FDGal PET/CT
- Where
- Denmark
- Volunteers
- 28 people
- Sponsor
- University of Aarhus
Hepatic Impairment, Healthy
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy…
- Trial name
- NCT06908954
- Testing
- Palovarotene
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Ipsen
Nonalcoholic Fatty Liver Disease
Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)
The primary objective is to test the hypothesis that 24 weeks of treatment with exenatide will improve the histological acitvity of NASH (steatosis,necroinflammation, ballooning), summarized in the recently introduced NASH-score…
- Trial name
- NCT01208649
- Testing
- Exenatide
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Ruhr University of Bochum
Hepatic Function Abnormal
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function
The purpose of this parallel group, Phase 1, open-label, 2-arm, single dose, multi-center study is to assess the effect of mild hepatic impairment on pharmacokinetics (PK), safety and tolerability of tolebrutinib compared with…
- Trial name
- NCT05283915
- Testing
- tolebrutinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sanofi
Advanced Solid Tumors
Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Panobinostat (LBH589) is a deacetylase inhibitor (DACi) which belongs to a structurally novel cinnamic hydroxamic acid class of compounds.
- Trial name
- NCT01007968
- Testing
- LBH589
- Where
- 6 sites in United States, Netherlands and 3 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
This study evaluates the pharmacokinetics (PK), safety, and tolerability of velzatinib in participants with mild, moderate, and severe hepatic impairment (HI) and participants with normal hepatic function.
- Trial name
- NCT07859735
- Testing
- Velzatinib
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
NASH
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of EDP-305 in subjects with mild and moderate hepatic impairment compared to matched healthy subjects.
- Trial name
- NCT03207425
- Testing
- EDP 305
- Where
- 3 sites in United States, Czechia and 1 more
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatic Impairment
Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
This is an open-label, non-randomized, multi-center, sequential group, safety, tolerance, and Pharmacokinetic study of a single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg in fasted…
- Trial name
- NCT05391724
- Testing
- CMX001
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Neoplasms, Lymphoma
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
Background: Pazopanib is an experimental drug that was designed to enter cancer cells and block the activity of proteins that are important for cancer cell growth and survival.
- Trial name
- NCT00674024
- Testing
- Pazopanib, Pazopanib (GW786034)(GW786034)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Subjects, Hepatic Impairment
The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics
This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of mild and moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of selatogrel (ACT-246475).
- Trial name
- NCT04406896
- Testing
- Selatogrel
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Liver Cirrhosis
Evaluation of Liver Regeneration With Autologous Peripheral Stem Cells
For patient with liver cirrhosis who need to right or extended right hepatectomy, we will treat with autologous peripheral stem cells transplantation to facilitate liver regeneration.
- Trial name
- NCT01108380
- Testing
- Plasma pheresis, Right portal vein embolization
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma (HCC), Radiofrequency Ablation
Ga-68 Dolacga PET Scan in HCC Under RFA
This study aims to investigate the use of Ga-68 Dolacga PET scan technology to assess treatment response and liver function changes in patients of early-stage liver cancer receiving RFA.
- Conditions
- Hepatocellular Carcinoma (HCC), Radiofrequency Ablation, PET Scan, Computed Tomography
- Trial name
- HCC; RFA (NCT06792097)
- Testing
- Ga-68 Dolacga PET scan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Hepatocellular, Alcoholic Cirrhosis
Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
The aim of the investigators' study is to elucidate the relationship between a functional liver test (e.g., ICG) and the PREOPERATIVE value of portal hypertension in the patients with impaired liver function from alcoholic and…
- Conditions
- Carcinoma, Hepatocellular, Alcoholic Cirrhosis, Viral Cirrhosis, Postoperative Hepatic Failure
- Trial name
- NCT00827723
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Lausanne Hospitals